Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive Phase 1 cohort 4 results for oral soquelitinib in moderate-to-severe atopic dermatitis. At Day 56 (n=12 soquelitinib, n=10 evaluable placebo) soquelitinib achieved EASI 75 in 75%, EASI 90 in 25% and IGA 0/1 in 33%, with mean EASI reduction of 72% vs 40% placebo and a statistically significant separation (p=0.035). Safety showed adverse events in 41.7% of treated patients vs 50% placebo; all events were Grade 1-2 with no serious adverse events. Biomarkers showed reductions in IL-4, IL-5, IL-17 and increased Treg cells. Corvus plans a ~200-patient Phase 2 trial in Q1 2026 with multiple dose arms and 12-week treatment.
Corvus Pharmaceuticals (NASDAQ: CRVS) will report results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT).
The company will host a conference call and live webcast with presentation slides; domestic dial-in is 1-800-717-1738 and international is 1-646-307-1865. The live webcast and slides are available via Corvus investor relations, and a replay will be available on the website for 60 days.
Corvus Pharmaceuticals (NASDAQ: CRVS) confirmed it will announce results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis in the second half of January 2026.
The company said the timing prompted cancellation of all previously planned conference attendance, including its presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026.
Corvus Pharmaceuticals (NASDAQ: CRVS) presented final Phase 1/1b data for soquelitinib in T cell lymphoma at ASH on Dec 8, 2025. Key clinical results in the 200 mg twice-daily cohort (N=36) included median PFS 6.2 months and median OS 28.1 months, with 6 complete responses and an 18-month PFS of 30% and 24-month OS of 67% in a defined responder subgroup (N=24).
No dose-limiting toxicities or significant adverse events were observed up to 600 mg BID. Biomarker data show ITK inhibition with Th1 skewing and reductions in Th2/Th17 markers. The company is running a randomized Phase 3 (target n=150) in relapsed/refractory PTCL with interim data expected late 2026 and completion in 2027; soquelitinib has Orphan Drug and Fast Track designations.
Corvus Pharmaceuticals (NASDAQ: CRVS) provided a business update and reported Q3 2025 results on Nov 4, 2025. Key clinical milestones include completed enrollment in the soquelitinib atopic dermatitis Phase 1 extension cohort 4 with data anticipated in Jan 2026, a Phase 2 atopic dermatitis trial on track to start in early Q1 2026 (≈200 patients), and an ongoing registrational Phase 3 in relapsed/refractory PTCL (target ≈150 patients) with final Phase 1/1b data to be presented orally at ASH Dec 2025.
Financials: cash, cash equivalents and marketable securities of $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026. R&D expense for Q3 2025 was $8.5M vs $5.2M year-ago; net loss was $10.2M for the quarter.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present final data from its Phase 1/1b trial of soquelitinib in relapsed/refractory T cell lymphomas at the 67th American Society of Hematology Annual Meeting & Exposition.
The oral presentation is scheduled for December 8, 2025, Session 625 (T Cell, NK Cell, or NK/T Cell Lymphomas), with a presentation slot from 11:15 AM–11:30 AM (session 10:30 AM–12:00 PM). Publication number is 778; the title reports final Phase 1 results for soquelitinib (SQL), an ITK inhibitor for R/R T cell lymphomas.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced that its leadership team will hold one-on-one investor meetings and deliver a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston.
The fireside chat is scheduled for Monday, November 10, 2025 at 8:30 AM ET. A live webcast will be available and archived for 90 days via the company’s investor relations website.
Corvus Pharmaceuticals (NASDAQ: CRVS) will provide a business update and report third quarter 2025 financial results on November 4, 2025. The company will host a conference call and live webcast at 4:30 pm ET / 1:30 pm PT. Participants can dial 1-800-717-1738 (toll-free U.S.) or 1-646-307-1865 (international), or join via the instant telephone access link and the company’s investor relations webcast page. A replay of the webcast will be available on the Corvus website for 90 days.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced interim Phase 1b/2 data (data cutoff May 2025) for ciforadenant combined with ipilimumab and nivolumab in first-line metastatic renal cell carcinoma presented at ESMO 2025 on October 17, 2025.
Key points: the open-label trial enrolled 50 patients, showed the triplet was feasible and well tolerated, deep response rate 34% versus ~32% historical doublet rate, objective response rate 46% (2 CR, 21 PR), median PFS 11.04 months, and 19 patients remain on therapy for longer follow-up.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced on October 2, 2025 the appointment of David Moore to its Board of Directors. Mr. Moore is Executive Vice President, US Operations and President at Novo Nordisk Inc., with 27 years of industry experience across strategy, commercial, market access, business development and private equity. Management expects his commercial and corporate development experience to support advancement of Corvus’ ITK inhibitor pipeline.